Clinical Trial Update: Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating calcium with or without estrogen and/or risedronate to prevent osteoporosis in men with prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Prostate Cancer

Drugs mentioned

• Calcium (Calcium)
• Estrogen (Estrogen)
• risedronate (risedronate)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Osteoporosis, Prostate Cancer | Phase 3 | Status: COMPLETED